

HETEROCYCLES, Vol. 82, No. 2, 2011, pp. 1601 - 1615. © The Japan Institute of Heterocyclic Chemistry
Received, 14th September, 2010, Accepted, 4th November, 2010, Published online, 11th November, 2010
DOI: 10.3987/COM-10-S(E)124

DESIGN AND SYNTHESIS OF PHOTOCLEAVABLE BIOTINYLATED-DOPAMINE WITH POLYETHYLENEOXY PHOTOCLEAVABLE LINKERS

Kengo Hanaya,[†] Yoshiyuki Kageyama,[†] Masanori Kitamura,^{†‡} and Shin Aoki^{†‡*}

Faculty of Pharmaceutical Sciences, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510 Japan and Center for Technologies against Cancer, Tokyo University of Science, 2641 Yamazaki, Noda 278-8510 Japan, E-mail: shinaoki@rs.noda.tus.ac.jp

Abstract – Previously, we reported the synthesis of a biotin–dopamine conjugate (Btn–DA) with a photocleavable 8-quinolinyI benzenesulfonate (QB) linker for the isolation of an intact complex of DA and anti-DA antibody (IgG₁) (DA–IgG₁ complex). In this work, we synthesized a photocleavable Btn–DA conjugate with a polyethyleneoxy linker to improve the complexation efficiency and the recovery yields of DA–IgG₁ complex. The results of QCM, ELISA, and Western blot analyses indicate that the introduction of polyethyleneoxy linkers improved the efficiency of DA–IgG₁ complexation.


INTRODUCTION

The isolation and identification of specific ligands and receptors of biologically active ligands such as proteins, peptides, and drugs are very important operations in the biological and medicinal sciences. The most popular method in these manipulations is affinity column chromatography that uses affinity resins, to which ligands are bound to trap specific receptor molecules. In this technique, avidin proteins (“avidin”)-coated resins and ligands modified with (+)-biotin (Btn) are often used (“avidin” includes three species of avidin proteins, as described below), because they form extraordinary stable complexes (K_d values \approx on the order of fM).¹ Due to the very stable “avidin”–Btn complexation, the separation of target molecules from the affinity matrix requires harsh denaturing conditions, such as treatment with detergent, high or low pH, high salt concentrations, and other similar conditions. To date, various attempts to obtain intact target receptors and/or ligand–receptor complexes (including Btn derivatives,²

This paper is dedicated to Professor Dr. Albert Eschenmoser on the occasion of his 85th birthday.

avidin mutant,³ and chemically,⁴ enzymatically⁵ or photochemically^{6a–c} cleavable Btn linkers) have been reported.

We recently reported that 8-quinolinylnyl benzenesulfonates (QB) (general structure: **1**) undergo photolysis upon UV irradiation at 300–330 nm in aqueous solution at neutral pH to give the corresponding 8-quinolinol **2** and benzenesulfonates **3** with very small amounts of byproducts.⁷ Mechanistic investigations have suggested that this photolytic reaction proceeds mainly via homolytic cleavage of the S–O bond in the excited triplet state (Scheme 1).⁸



Scheme 1

We applied this photochemical cleavage reaction of QB to a photocleavable linker. We designed and synthesized a biotin–dopamine (Btn–DA) conjugate with a QB linker **4** (Figure 1). Complexation of **4** with anti-DA antibody (IgG₁) on an “avidin”-coated surface and the photochemical release of **4**–IgG₁ complex were confirmed by 27-MHz quartz-crystal microbalance (QCM) experiments and enzyme-linked immunosorbent assay (ELISA).⁹ However, the efficiency of the recovery of IgG₁ using **4** was not so high. Because we assumed that steric hindrance between “avidin” and IgG₁ may hamper the efficient complexation of the DA part of **4** with IgG₁, we designed and synthesized **5**, which has longer linkers than those of **4** (Figure 1) in this work. We also compared the complexation of **5** with IgG₁ and the recovery efficiency of the photorelease of IgG₁ to those of **4** by QCM, ELISA, and Western blot analyses.




Figure 1


RESULTS AND DISCUSSION

Synthesis of biotinylated dopamine **5** with a polyethyleneoxy linker

The synthesis of **5** was carried out similarly to that of **4** (Scheme 2).⁹ (+)-Biotin **6** was reacted with *N*-Boc-1,8-bis(aminomethyl)-3,6-dioxaoctane **7**¹⁰ to give **8**,¹¹ the Boc group of which was deprotected by treatment with trifluoroacetic acid (TFA) to afford **9**. The treatment of **9** with **10**¹² gave **11**. For the alkyne part, *N*-Fmoc- ϵ -aminocaproic acid **12**¹³ was reacted with propargylamine **13** to give **14**, the Fmoc group of which was deprotected (piperidine, THF) to afford **15**. The reaction of **15** with 4-(chlorosulfonyl)phenylisocyanate **16** gave **17**,¹⁴ which was successively reacted with **11** to yield **18**. Huisgen 1,3-dipolar [3+2] cycloaddition of the terminal alkyne group of **18** with **19**⁹ in the presence of a catalytic amount of Cu²⁺ and sodium ascorbate according to the procedures of click chemistry¹⁵ gave **20** in moderate yields. Finally, deprotection of the TBDMS groups of **20** by treatment with HCl/dioxane gave **5** as the HCl salt.

Evaluation of the complexation properties of **4** and **5** with neutravidin (Nevn) and anti-DA antibody (IgG₁) using a 27-MHz quartz-crystal microbalance (QCM)

The complexation of **4** and **5** with "avidin" was studied by means of a 27-MHz quartz-crystal microbalance (QCM), as we previously reported.¹⁶ "Avidin" proteins are classified into three categories, avidin (Avn) isolated from egg white, neutravidin (Nevn), which is deglycosylated form of avidin,^{1g} and streptavidin (Stvn) isolated from the bacterium *Streptomyces avidinii*.¹ It is described that the K_d values for the complexes of these "avidin" species with biotin are almost equal.^{1a, 1f, 1g} In this QCM titrations, Nevn was used to minimize nonspecific binding. The complexation constants, K_{s1} , of **4** and **5** with Nevn were determined to be $10^{(8.2 \pm 0.2)} \text{ M}^{-1}$ and $10^{(7.6 \pm 0.5)} \text{ M}^{-1}$, respectively. The K_{s1} value for photocleavable biotin linker **18**, which lacks the DA part, was determined to be $10^{(8.1 \pm 0.2)} \text{ M}^{-1}$, indicating that the introduction of DA to the biotin linker has a negligible effect on the K_{s1} value. In addition, anti-DA antibody (IgG₁) was added to the Nevn-**4** and Nevn-**5** complexes to obtain the QCM titration curves, from which the K_{s2} values for complexation of the Nevn-**4** and Nevn-**5** complexes with IgG₁ were estimated to be $10^{(7.5 \pm 0.3)} \text{ M}^{-1}$ and $10^{(7.1 \pm 0.9)} \text{ M}^{-1}$, respectively.



Scheme 2

Verification of the complexation of **5** with anti-dopamine antibody and comparison to that of **4** by enzyme-linked immunosorbent assay (ELISA)

The complexation of **5** with IgG₁ was compared with that of **4** by ELISA (Scheme 3).⁹ In these experiments, commercially available Stvn-coated 96-well plates (**21**) were used to react with **4** or **5** to prepare Stvn-**4** (or **5**) complexes in the wells (**22**), to which IgG₁ was added to obtain the ternary complex **23**. In Scheme 3, Stvn and Avn that have tetrameric structures are illustrated as a monomer form for simplicity. After **23** was washed with phosphate-buffered saline containing 0.05% (v/v) Tween 20 (PBST), the **22**-IgG₁ complex **23** was treated with an anti-IgG antibody conjugated with horseradish peroxidase (secondary IgG-HRP conjugate, 2nd IgG-HRP) to give **24**, as indicated on the left half of Scheme 3. HRP-catalyzed oxidative dimerization of *o*-phenylenediamine (OPD) using H₂O₂ gave 2,3-diaminophenazine, which has an absorption maximum at 450 nm (OD₄₅₀).¹⁷ Figure 2 shows the increases in the OD₄₅₀ values with increasing concentrations of **4** and **5**, which strongly suggests the formation of quaternary complex **24** (Stvn-**4** (or **5**)-IgG₁-2nd IgG-HRP). Note that larger OD₄₅₀ values were observed with **5** than with **4**, which suggests that the complexation with IgG₁ was somewhat improved and/or the rate of the enzymatic reaction was enhanced possibly by reduction of the steric hindrance around HRP.





Figure 2. Results of ELISA using **4** (open circles) and **5** (closed circles). The data were normalized with the value obtained with 0.8 $\mu\text{g}\cdot\text{mL}^{-1}$ of **5**.



Scheme 3

Photoreaction of the complexes of 4 or 5 with anti-dopamine antibody (IgG₁) on avidin (Avn)-beads, examined by ELISA and Western blot analysis.

Photocleavage of the 5-IgG₁ complex in Stvn-coated 96-well plates was carried out by photoirradiation at 313 nm using a 500 W high pressure mercury-vapor lamp (USHIO), as shown on the right half of Scheme 3. After irradiation of the ternary complex (**23**→**25** in Scheme 3), the amount of remaining **23** was analyzed by ELISA. As shown in Figure 3, OD_{450} decreased with an increase in the duration of photoirradiation, suggesting that the DA-IgG₁ complex is released from the wells in a similar efficiency as that of **4**.




Figure 3. Results of ELISA using **4** (open circles) and **5** (closed circles) after photoirradiation at 313 nm. These data were normalized with the OD₄₅₀ values of **4** and **5** before photoirradiation, respectively.

The photoreaction products **26** (Scheme 3) were analyzed by Western blotting. In this experiment, Avn-agarose (Avn-coated) beads were used as the solid phase instead of Stvn-coated 96-well plates. Lane 1 is the sample obtained by treatment of the **4** (or **5**)–IgG₁ complex on Avn-agarose beads with SDS without photoirradiation. Lanes 2 and 3 show that the amount of photoreleased DA–IgG₁ complex depends on the duration of photoirradiation (lane 2, 0 min; lane 3, 30 min), and the amounts of photoreleased DA–IgG₁ with **4** and **5** were almost identical, which agreed fairly well with the results of ELISA shown in Figure 3. Comparison of the products after photoreaction (Lane 3 in Figure 4a and b) and the products after SDS treatment without photoirradiation (Lane 1 in Figure 4a and b) indicated that the recovery efficiencies of DA–IgG₁ from **4** and **5** were almost the same.

Discussion about the amount of isolated IgG₁ using these data is not easy, because these experiments may give only qualitative data, due to the use of polyclonal anti-IgG₁ antibody in ELISA and Western blotting and the signals in these experiments are amplified by enzymatic reaction of HRP. In addition, the discrepancy between the results of ELISA and Western blotting may be due to the use of different solid phases and detection methods in two methods (Stvn-coated 96-wells plates for ELISA and avidin-coated beads for Western blotting). For instance, the results of our recent experiments suggested that chemical properties and/or shapes of solid phase may affect the photoreactivity of QB linker (details will be reported elsewhere).




Figure 4. Results of Western blotting of a) **4**-IgG₁ complex and b) **5**-IgG₁ complex after the photoreaction. Lane 1: The sample obtained by treatment of **4** or **5**-IgG₁ with SDS without photoirradiation. Lanes 2, 3: Photoproducts after photoirradiation (313 nm) for 0 min and 30 min, respectively. Lane 4: Blank. Lane 5: Anti-dopamine antibody (IgG₁) obtained commercially and used for QCM, ELISA, and Western blotting.

CONCLUSION

In this report, we described the design and synthesis of a biotinylated dopamine **5** that contained photocleavable linkers that are longer than those of **4**. The photocleavable biotin-linker can be easily incorporated into target molecules using a Huisgen 1,3-dipolar [3+2] cycloaddition or other coupling reactions. We found that the efficiency of complexation of **5** with DA-IgG₁ was somewhat greater than that of **4** and the photoreactivities of the complexes of **4** and **5** with IgG₁ were almost identical. These methods may provide effective strategies for the recovery of intact ligand-receptor complexes under mild conditions, without the need for damaging chemical reagents. The isolation of dopamine receptors using this methodology is now under way.

EXPERIMENTAL

All reagents and solvents purchased were of the highest commercial quality and used without further purification. All aqueous solutions were prepared using deionized and distilled water. IR spectra were recorded on a Horiba FTIR-710 spectrophotometer at room temperature. ¹H (300 MHz) and ¹³C (75 MHz) NMR spectra were recorded on a JEOL Always 300 spectrometer. Thin-layer (TLC) and silica gel column chromatography were performed using Merck 5554 (silica gel) TLC plates and Fuji Silysia Chemical FL-100D, respectively.

Compound 8: A solution of (+)-biotin **6** (55 mg, 0.227 mmol), *N*-Boc-1,8-bis(methylamino)-3,6-dioxaoctane **7**¹⁰ (69 mg, 0.250 mmol) and 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC·HCl) (57 mg, 0.235 mmol) in a mixture of MeOH and MeCN (1:3) (20 mL) was stirred for 6 h at room temperature and the reaction

mixture was concentrated under reduced pressure. The residue was resuspended in MeOH and filtered through celite (No. 545). The filtrate was concentrated under reduced pressure and the residue was purified by silica gel column chromatography (CH₂Cl₂/MeOH, 10:1) to yield **8** as a pale yellow oil (103 mg, 90% yield). IR (KBr) 3264, 3073, 2974, 2929, 2867, 1698, 1638, 1458, 1396, 1161, 1119 cm⁻¹; ¹H NMR (CDCl₃) δ = 1.45 (10H, s), 1.67—1.78 (4H, m), 2.32—2.42 (2H, m), 2.74 (1H, d, *J* = 12.8 Hz), 2.88—3.07 (7H, m), 3.18 (1H, dt, *J* = 4.8, 4.8 Hz), 3.39 (2H, br), 3.48—3.67 (10H, m), 4.32 (1H, m), 4.46 (1H, m). ¹³C NMR (CDCl₃) δ = 24.8, 25.2, 28.2, 28.3, 28.4, 28.5, 32.4, 33.0, 33.7, 33.9, 37.1, 40.5, 47.7, 49.7, 51.6, 55.4, 55.5, 60.1, 61.8, 61.9, 69.0, 69.6, 70.3, 70.8, 79.4, 163.6, 173.0, 173.4, 174.1.

Compound 11: TFA (0.2 mL) was added to a solution of **8** (100 mg, 0.199 mmol) in CH₂Cl₂ (3 mL) and the mixture was stirred for 3 h at room temperature. After the reaction mixture was concentrated under reduced pressure, the resulting residue was azeotroped with toluene to remove TFA. The residue was dissolved in CHCl₃ and the solution was washed with 1 N aqueous NaOH. After the organic layers were dried over Na₂SO₄, the solvent was filtered and concentrated under reduced pressure to yield crude **9** as a colorless oil (79 mg, 98% crude yield). IR (KBr) 3298, 3092, 2923, 2863, 1702, 1636, 1459, 1117 cm⁻¹; ¹H NMR (CDCl₃) δ = 1.44—1.52 (2H, m), 1.63—1.76 (4H, m), 2.33—2.44 (2H, m), 2.45 (2H, s), 2.72—2.78 (3H, m), 2.89—3.07 (3H, m), 3.15—3.19 (1H, m), 3.47—3.65 (10H, m), 4.30—4.34 (1H, m), 4.49—4.51 (1H, m).

Et₃N (42 μL, 0.3 mmol) was added to a solution of crude **9** in CH₂Cl₂ (8 mL) at 0 °C under an argon atmosphere, and then a solution of **10** (39 mg, 0.150 mmol)¹² in CH₂Cl₂ (2 mL) was added dropwise. The reaction mixture was stirred for 30 min at 0 °C and overnight at room temperature. The solvent was removed under reduced pressure and the remaining residue was purified by silica gel column chromatography with a CH₂Cl₂-MeOH gradient (1:0, 50:1, 30:1 v/v) as solvent to yield **11** as a yellow amorphous solid (81 mg, 87% yield). IR (KBr) 3422, 2928, 2867, 1702, 1636, 1325, 1175, 1115 cm⁻¹; ¹H NMR (CDCl₃) δ = 1.45—1.47 (2H, m), 1.65—1.70 (4H, m), 2.32—2.39 (2H, m), 2.72 (1H, d, *J* = 13.1 Hz), 2.76 (3H, s), 2.80 (3H, s), 2.90—3.05 (4H, m), 3.17—3.19 (1H, m), 3.34 (2H, t, *J* = 5.7 Hz), 3.46—3.68 (8H, m), 4.33—4.35 (1H, m), 4.53 (1H, m), 7.15 (1H, d, *J* = 8.2 Hz), 7.48 (1H, d, *J* = 8.8 Hz), 8.08 (1H, d, *J* = 8.2 Hz), 8.91 (1H, d, *J* = 8.8 Hz); ¹³C NMR (CDCl₃) δ = 24.7, 24.7, 25.1, 28.2, 28.3, 30.3, 32.3, 32.9, 33.8, 35.6, 35.6, 37.0, 40.5, 47.6, 49.0, 49.6, 55.3, 60.1, 61.7, 68.8, 69.4, 69.7, 70.1, 70.4, 70.7, 108.0, 123.3, 123.3, 124.4, 131.5, 134.3, 137.6, 156.2, 157.9, 163.3, 172.9, 173.3; MS (FAB+) *m/z* 624.2526 (calcd for C₂₈H₄₂N₅O₇S₂: 624.2520).

Compound 15: EDC·HCl (141 mg, 0.736 mmol) and propargylamine **13** (31 mg, 0.566 mmol) were added to a solution of **12**¹³ (200 mg, 0.566 mmol) in a 1/1 mixture of MeOH and MeCN (3 mL). The

reaction mixture was stirred overnight at room temperature and the solvent was removed under reduced pressure. The remaining residue was resolved in CHCl_3 and the solution was washed with water, dried over Na_2SO_4 , and filtered. After the filtrate was concentrated under reduced pressure, the resulting residue was purified by silica gel chromatography (CHCl_3) to yield **14** as a colorless solid (209 mg, 94% yield). ^1H NMR (CDCl_3) δ = 1.25—1.38 (2H, m), 1.52—1.56 (2H, m), 1.67—1.70 (2H, m), 2.18—2.21 (3H, m), 3.20 (2H, td, J = 6.4, 6.4 Hz), 4.50 (2H, dd, J = 2.6, 5.3 Hz), 4.21 (1H, t, J = 7.0 Hz), 4.40 (2H, d, J = 7.0 Hz), 7.31 (2H, dd, J = 7.3, 7.3 Hz), 7.40 (2H, dd, J = 7.3, 7.3 Hz), 7.59 (2H, d, J = 7.3 Hz), 7.77 (2H, d, J = 7.3 Hz)

Piperidine (600 μL) was added to a solution of **14** (90 mg, 0.230 mmol) in THF (3 mL) and the reaction mixture was stirred for 1 h at room temperature. After the solvent was removed under reduced pressure, the resulting solid was resuspended in Et_2O and filtered to yield **15** (40 mg, quant) as a colorless solid. IR (neat) 3290, 2931, 2859, 1637, 1541 cm^{-1} ; ^1H NMR (CDCl_3) δ = 1.32—1.50 (4H, m), 1.67 (2H, tt, J = 7.5, 7.5 Hz), 2.19—2.24 (3H, m), 2.70 (2H, t, J = 6.8 Hz), 4.06 (2H, dd, J = 2.6, 5.1 Hz); ^{13}C NMR (CD_3OD) δ = 26.5, 27.3, 29.4, 32.2, 36.6, 72.0, 80.7, 175.7; MS (FAB+) m/z 169.1342 (calcd for $\text{C}_9\text{H}_{17}\text{N}_2\text{O}$: 169.1335).

Compound 18: Compound **15** (39 mg, 0.230 mmol) was added to a solution of 4-(chlorosulfonyl)phenyl isocyanate **16** (50 mg, 0.230 mmol) in THF (3 mL). The reaction mixture was stirred for 3 h at room temperature and the solvent was removed to give crude **17** as a yellow solid. A solution of crude **17** (18 mg) in THF (0.5 mL) and 4-*N,N*-dimethylaminopyridine (2 mg) was added to a mixture of **11** (29 mg, 0.047 mmol) and diisopropylethylamine (6 mg, 0.048 mmol) in CH_2Cl_2 (2 mL) at 0 $^\circ\text{C}$, and the reaction mixture was stirred overnight at reflux. After the solvent was removed, the remaining residue was dissolved in CHCl_3 and washed with water. The organic layer was dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with a CHCl_3 -MeOH gradient (1:0, 30:1, 25:1, 20:1, 13:1 v/v) to yield **18** as a colorless amorphous solid (22 mg, 48% yield based on **11**). IR (KBr) 3427, 3266, 2928, 2861, 1697, 1634, 1372, 1321, 1223, 1169, 1142, 1112 cm^{-1} ; ^1H NMR (CDCl_3) δ = 1.25—1.67 (10H, m), 2.19—2.24 (3H, m), 2.31 (2H, m), 2.63 (3H, s), 2.76 (1H, d, J = 13.0 Hz), 2.84—3.00 (7H, m), 3.15—3.24 (3H, m), 3.37—3.54 (12H, m), 4.33 (1H, m), 4.53 (1H, m), 7.37 (1H, d, J = 8.9 Hz), 7.49—7.63 (3H, m), 7.69—7.76 (2H, m), 8.08 (1H, d, J = 8.4 Hz), 8.83 (1H, d, J = 8.9 Hz); ^{13}C NMR (CDCl_3) 24.6, 25.0, 25.3, 26.2, 27.6, 27.8, 29.1, 29.3, 29.7, 31.0, 32.5, 36.0, 36.9, 39.4, 40.5, 47.5, 49.2, 55.3, 60.3, 61.7, 68.6, 69.0, 69.1, 70.1, 70.2, 70.5, 71.5, 79.6, 117.0, 120.7, 120.9, 124.1, 127.8, 130.2, 133.3, 133.4, 133.6, 141.5, 146.3, 148.8, 155.3, 160.7, 163.6, 173.1, 173.3, 173.5. MS (FAB+) m/z 973.3619 (calcd for $\text{C}_{44}\text{H}_{61}\text{N}_8\text{O}_{11}\text{S}_3$: 973.3622).

Compound 20: Sodium ascorbate (1.0 μmol , 10 μL of a 100 mM solution in water) and $\text{CuSO}_4 \cdot 5\text{H}_2\text{O}$ (0.5 μmol , 5 μL of a 100 mM solution in water) were added to a suspension of **18** (10 mg, 10 μmol) and **19**⁹ (5 mg, 10 μmol) in a 1/1 mixture of water and THF (1mL). The reaction mixture was stirred overnight at room temperature, and the solvent was removed under reduced pressure. After the remaining residue was resuspended in CHCl_3 , the solution was washed with water, dried over Na_2SO_4 , filtered, and concentrated under reduced pressure. The resulting residue was purified by silica gel column chromatography with a CH_2Cl_2 -MeOH gradient (15:1, 13:1, 10:1 v/v) to yield **20** as a pale yellow amorphous (10 mg, 63% yield). ^1H NMR (CDCl_3) δ = 0.18 (12H, s), 0.94 (18H, s), 1.33—1.70 (12H, m), 2.21—2.32 (4H, m), 2.61 (3H, s), 2.73—2.76 (1H, m), 2.85—2.98 (11H, m), 3.12 (1H, m), 3.21 (2H, td, J = 5.9, 11.8 Hz), 3.38—3.54 (14H, m), 4.53—4.54 (3H, m), 6.64 (1H, d, J = 8.0 Hz), 6.68 (1H, s), 6.74 (1H, d, J = 8.0 Hz), 7.35 (1H, d, J = 8.9 Hz), 7.43 (2H, d, J = 7.8 Hz), 7.49 (2H, d, J = 9.0 Hz), 7.56—7.61 (3H, m), 7.71 (2H, d, J = 9.0 Hz), 8.00 (1H, s), 8.07 (1H, d, J = 8.3Hz), 8.83 (1H, d, J = 8.9 Hz).

Compound 5: 4N HCl in dioxane (57 μL , 0.228 mmol) was added to a solution of **20** in a 1/1 mixture of MeOH and THF (1 mL), and the reaction mixture was stirred overnight at room temperature. After the solvent was removed under reduced pressure, the remaining residue was purified by silica gel column chromatography with a CHCl_3 -MeOH gradient (5:1, 4:1, 3:2 v/v) to yield **5** as a colorless amorphous solid (8 mg, 96% yield). IR (KBr) 3422, 2969, 2932, 2871, 2819, 1685, 1611, 1373, 1325, 1170, 1057, 1033, 1015 cm^{-1} ; ^1H NMR (CD_3OD) δ = 1.37—1.68 (12H, m), 2.26 (2H, t, J = 7.6 Hz), 2.38 (2H, m), 2.56 (3H, s), 2.65 (1H, dd, J = 5.9 Hz), 2.84—3.06 (10H, m), 3.22—3.34 (3H, m), 3.39 (2H, m), 3.46—3.63 (12H, m), 4.27 (3H, m), 4.44 (1H, m), 4.56 (2H, s), 6.58 (1H, d, J = 8.0 Hz), 6.68 (1H, s), 6.73 (1H, d, J = 8.0 Hz), 7.43 (1H, d, J = 8.9 Hz), 7.48 (1H, d, J = 9.1Hz), 7.66 (2H, d, J = 8.4 Hz), 7.67 (2H, d, J = 8.9 Hz), 7.76 (1H, d, J = 8.0 Hz), 7.93 (2H, d, J = 8.4 Hz), 8.15 (1H, d, J = 8.0Hz), 8.43 (1H, s), 8.87 (1H, d, J = 9.1 Hz). MS (FAB+) m/z 1257.4893 (Calcd for $\text{C}_{59}\text{H}_{77}\text{N}_{12}\text{O}_{13}\text{S}_3$: 1257.4895).

Determination of K_s values for 4 and 5 with Nevn and anti-DA IgG₁ by 27-MHz quartz-crystal microbalance (QCM) analysis: QCM experiments were performed on an Affinix-Q4 apparatus (Initium Inc., Japan).¹⁶ In QCM experiments, Nevn was used to minimize nonspecific binding. A clean Au (4.9 mm^2) electrode on a quartz crystal was incubated with an aqueous solution of 3,3'-dithiodipropionic acid (3 mM) at room temperature for 45 min. The surfaces were activated by treatment with a mixture of EDC·HCl (0.26 M) and *N*-hydroxysuccinimide (0.44 M) for 45 min. The chip was allowed to stand to reach equilibrium at 25 °C in 500 μL phosphate-buffered saline (PBS). Next, 5 μL of Nevn solution (1 mg/mL) was injected and the change in the frequency of the quartz

oscillator was recorded at specific time points. After 1 μL of an aqueous solution of ethanolamine (1 M) was added to block the remaining activated groups, PBS was replaced with PBST. For the immobilization of Nevn-**4** or **5**, 1 μL of an aqueous solution of **4** or **5** (0.5 $\mu\text{g}/\text{mL}$) was injected at several time points and the change in frequency was recorded. Based on the fact that a frequency decrease (ΔF) of 1 Hz corresponds to a mass increase of 30 pg on the electrode (0.049 cm^2), K_{s1} values were determined from the relationship between the decrease in frequency and the time for equilibration. To determine the K_{s2} values for Nevn-**4** or -**5** complexes and IgG₁, Nevn-**4** or -**5** complexes, which had been prepared beforehand, was immobilized on a Au electrode. 1 μL of an aqueous solution of IgG₁ was injected at several time points and K_{s2} values were determined as described above.

ELISA: A monoclonal anti-dopamine antibody (IgG₁) (Abcam) was used as a primary antibody. A streptavidin-immobilized 96-well plate was purchased from Nunc Co. Ltd and washed three times with phosphate-buffered saline containing 0.05% (w/v) Tween 20 (PBST) prior to use. The biotinylated dopamine **4** or **5** diluted with PBST was added at 100 $\mu\text{L}/\text{well}$, and the plates were then incubated at room temperature for 1 h. After being washed with PBST, the **4** or **5** in each well was sequentially incubated at room temperature for 1 h with IgG₁ (1:2500 dilution) and 2nd IgG-HRP conjugate (1:1000 dilution), and the plates were incubated for 1 h at room temperature. After the plates were washed, OPD and H₂O₂ were added to each well. After incubation at room temperature for 15 min, the absorbance at 450 nm was measured on a Bio-Rad model 550 microplate reader (Bio-Rad, Hemel, Hempstead, UK).

Photoreaction for the release of DA-IgG₁ complex: Stvn-coated wells were treated with **4** or **5** and IgG₁ as described above and photoirradiated at 313 nm using a USHIO Optical Module X equipped with a high pressure mercury-vapor lamp (USHIO), a UV-transmitting and visible-absorbing filter (U-330, Kenko, Co. Ltd., Japan), and an optical filter (HQBP313-UV, Asahi Spectra, Co. Ltd., Japan). After irradiation for defined durations, the wells were washed with PBST (100 μL) and 2nd IgG-HRP (diluted 1:1000 with PBST) was added to the wells. After the samples were incubated at room temperature and washed, OPD and H₂O₂ were added and the absorbance was measured at 450 nm on a Bio-Rad model 550 microplate reader (Bio-Rad, Hemel, Hempstead, UK).

Western blotting: Avidin-agarose (Avn-coated) beads (Sigma-Aldrich) were reacted with **4** or **5** in PBST at room temperature for 2 h, washed three times with PBST, and then reacted with IgG₁ at room temperature for 1 h. After the resulting avidin beads were washed three times with PBST, the beads were resuspended in 0.5 mM Tris-HCl buffer and then transferred to a 24-well plate. These suspensions were photoirradiated at 313 nm as described above to release DA-IgG₁ complexes. The resulting

mixture was filtered through DISMIC-13HP PTFE (0.45 μm , ADVANTEC) to remove the beads. The precipitate was washed with 5 mM Tris-HCl buffer and the combined filtrate was freeze-dried. The resulting materials were dissolved in a mixture of 10% SDS (8 μL), glycerol (4 μL), and water (8 μL), loaded on 15% SDS-polyacrylamide gel for electrophoresis (20 $\mu\text{L}/\text{lane}$), and then transferred to a PVDF membrane (Immobilon-P Transfer Membrane, Millipore) under wet conditions. The membrane was blocked with 3% bovine serum albumin (BSA, Sigma) and incubated with 2nd IgG₁-HRP diluted with PBST for 1 h at room temperature. The membrane was rinsed with Tris-buffered saline containing 0.05% (w/v) Tween20 (5 minutes \times 3) and visualized using ECL Plus Western blotting detection reagents on a LAS 3000 lumino-image analyzer (FUJIFILM).

ACKNOWLEDGEMENTS

This study was supported by grants-in-aid from the Ministry of Education, Culture, Sports, Science and Technology (MEXT) of Japan (No. 18390009, 19659026, 22390005, and 22659005) and the "Academic Frontier" project for private universities: matching fund subsidy from MEXT, 2009—2013. M. K. is also thankful for a Sasakawa Scientific Research Grant from the Japan Science Society.

REFERENCES (AND NOTES)

†Faculty of Pharmaceutical Sciences, Tokyo University of Science

‡Center for Technologies against Cancer, Tokyo University of Science

- (a) 'Methods in Enzymology: Avidin Biotin Technology,' ed. by M. Wilchek and E. A. Bayer, Academic Press, Inc., San Diego, 1990; (b) 'A Laboratory Guide to Biotin-Labeling in Biomolecule Analysis,' ed. by T. Meier and F. Fahrenholz, Birkhauser, Boston, 1996; (c) 'Biotin,' Icon Group Intl., Inc., San Diego, 2004; (d) K. Hofmann and Y. Kiso, *Proc. Natl. Acad. Sci. U.S.A.*, 1976, **73**, 3516; (e) M. Wilchek and E. A. Bayer, *Anal. Biochem.*, 1988, **171**, 1; (f) E. P. Diamandis and T. K. Christopoulos, *Clin. Chem.*, 1991, **37**, 625; (g) Y. Hiller, J. Gershoni, E. A. Bayer, and M. Wilchek, *Biochem. J.*, 1987, **248**, 167.
- (a) K. Hofmann, G. Titus, J. A. Montibeller, and F. M. Finn, *Biochemistry*, 1982, **21**, 978; (b) K. Hofmann, W. J. Zhang, H. Romovacek, F. M. Finn, A. A. Bothner-By, and P. K. Mishra, *Biochemistry*, 1984, **23**, 2547; (c) J. D. Hirsch, L. Eslamizar, B. J. Filanoski, N. Malekzadeh, R. P. Haugland, J. M. Beechem, and R. P. Haugland, *Anal. Biochem.*, 2002, **308**, 343; (d) B. Fudem-Goldin and G. A. Orr, *Methods Enzymol.*, 1990, **184**, 167.
- (a) G. O. Reznik, S. Vajda, T. Sano, and C. R. Cantor, *Proc. Natl. Acad. Sci. U.S.A.*, 1998, **95**, 13525; (b) K. P. Henrikson, S. H. G. Allen, and W. L. Maloy, *Anal. Biochem.*, 1979, **94**, 366.

4. (a) M. Shimkus, J. Levy, and T. Herman, *Proc. Natl. Acad. Sci. U.S.A.*, 1985, **93**, 2593; (b) G. A. Soukup, R. L. Cerny, and L. J. Maher, *Bioconjugate Chem.*, 1995, **6**, 135; (c) Y. -S. Kang, K. Voigt, and U. J. Bickerl, *Drug Targeting*, 2000, **8**, 3425; (d) W.-C. Lin and T. H. Morton, *J. Org. Chem.*, 1991, **56**, 6850; (e) P. van der Veken, E. H. C. Dirksen, E. Ruijter, R. C. Elgersma, A. J. R. Heck, D. T. S. Rjiker, M. Slijper, and R. M. L. Liskamp, *ChemBioChem*, 2005, **6**, 2271.
5. S. Sato, Y. Kwon, S. Kamisuki, N. Srivastava, Q. Mao, Y. Kawazoe, and M. Uesugi, *J. Am. Chem. Soc.*, 2007, **129**, 873.
6. (a) J. Olejnik, S. Sonar, E. Krzymanska-Olejnik, and K. J. Rothschild, *Proc. Natl. Acad. Sci. U.S.A.*, 1995, **92**, 7590; (b) M. W. Pandori, D. A. Hobson, J. Olejnik, E. Krzymanska-Olejnik, K. J. Rothchild, A. A. Palmer, T. J. Phillips, and T. Sano, *Chem. Biol.*, 2002, **9**, 567; (c) J. Olejnik, E. Krzymanska-Olejnik, and K. J. Rothchild, *Nucl. Acids Res.* 1996, **24**, 361; (d) J. J. Park, Y. Sadakane, K. Masuda, T. Tomohiro, T. Nakano, and Y. Hatanaka, *ChemBioChem*, 2005, **6**, 814.
7. (a) S. Aoki, K. Sakurama, R. Ohshima, N. Matsuo, Y. Yamada, R. Takasawa, S. Tanuma, and K. Takeda, *Inorg. Chem.*, 2008, **47**, 2747; (b) R. Ohshima, M. Kitamura, A. Morita, M. Shiro, Y. Yamada, M. Ikekita, E. Kimura, and S. Aoki, *Inorg. Chem.*, 2010, **49**, 888.
8. Y. Kageyama, R. Ohshima, K. Sakurama, Y. Fujiwara, Y. Tanimoto, Y. Yamada, and S. Aoki, *Chem. Pharm. Bull.*, 2009, **57** 1257.
9. S. Aoki, N. Matsuo, K. Hanaya, Y. Yamada, and Y. Kageyama, *Bioorg. Med. Chem.*, 2009, **17**, 3405.
10. (a) R. J. Amir, N. Pessah, M. Shamits, and D. Shabat, *Angew. Chem. Int. Ed.*, 2003, **42**, 4494; (b) T. M. Fyles and C. Hu, *J. Supramol. Chem.*, 2003, **1**, 207.
11. A. Eiseführ, S. P. Arora, G. Sengle, R. L. Takaoka, S. J. Nowick, and M. Famulok, *Bioorg. Med. Chem.*, 2003, **11**, 235.
12. (a) D. A. Pearce, N. Jotterand, I. S. Carrico, and B. Imperiali, *J. Am. Chem. Soc.*, 2001, **123**, 5160; (b) S. Aoki, K. Sakurama, N. Matsuo, Y. Yamada, R. Takasawa, S. Tanuma, M. Shiro, K. Takeda, and E. Kimura, *Chem. Eur. J.*, 2006, **12**, 9066.
13. A. Paquet, *Can. J. Chem.*, 1982, **60**, 976.
14. J. Leban, S. Pegoraro, M. Dormeyer, M. Lanzer, A. Aschenbrenner, and B. Kramer, *Bioorg. Med. Chem. Lett.*, 2004, **14**, 1979.
15. (a) H. C. Kolb and K. B. Sharpless, *Drug Discov. Today*, 2003, **24**, 1128; (b) V. D. Bock, H. Hiemstra, and J. H. van Maarseveen, *Eur. J. Org. Chem.*, 2006, 51; (c) W. G. Lewis, L. G. Green, F. Grynszpan, Z. Radić, P. R. Carlier, P. Taylor, M. G. Finn, and K. B. Sharpless, *Angew. Chem. Int. Ed.*, 2002, **41**, 1053; (d) V. V. Rostovtsev, L. G. Green, V. V. Fokin, and K. B. Sharpless, *Angew. Chem. Int. Ed.*, 2002, **41**, 2596.
16. (a) Y. Okahata, Y. Matsunobu, K. Ijiro, M. Mukai, A. Murakami, and K. Makino, *J. Am. Chem. Soc.*,

- 1992, **114**, 8299; (b) Y. Okahata, M. Kawase, K. Niikura, F. Ohtake, H. Furusawa, and Y. Ebara, *Anal. Chem.*, 1998, **70**, 1288; (c) H. Nishino, T. Nihira, T. Mori, and Y. Okahata, *J. Am. Chem. Soc.*, 2004, **126**, 2264.
17. (a) P. J. Tarche, V. P. Chu, and D. Whittern, *Anal. Biochem.*, 1987, **165**, 230; (b) H. Liu, Z. Wang, Y. Liu, J. Xiao, and C. Wang, *Thermochim. Acta*, 2006, **443**, 173.